EUVIMEDEUVIMED entdecken
Crossref

Pyrimidine‐Derived Scaffolds Targeting VEGFR‐2, EGFR, and HER‐2: Synthesis, Anticancer/Immunomodulatory Evaluation, and In Silico Analysis

Naglaa M Ahmed, Mohamed S Gaballah, Belen Altava, Ahmed H Lotfallah

Drug Development Research · 2026-05 · 87 (3)

DOI: 10.1002/ddr.70314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 12.05.2026. Verfasst von Naglaa M Ahmed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Ain-Helwan, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Vascular Endothelial Growth Factor Receptor-2, Pyrimidines, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following the common structural features of VEGFR‐2, EGFR, and HER‐2 kinase inhibitors, two newly synthesized series of 3,4‐dihydropyrimidine 2(1 H )‐(thio)ones‐5‐carboxamide ( 2a–l ) and thiouracil‐5‐sulfonyl derivatives ( 4a–e ) were evaluated for anti‐proliferative activity against colorectal (HCT‐116) and breast ( MCF‐7) cancer cell lines. Among the designed series, Compounds 2h and 2l were the most potent derivatives across both tumor models, exhibiting IC 50 values of 23.3 and 30.9 μM (HCT‐116), respectively, and 31.5 and 39.2 μM (MCF‐7), respectively, compared to sorafenib (IC 50 = 8.8 and 11.6 μM, respectively). Interestingly, 2h and 2l displayed a favorable safety profile toward the normal human cell line WI‐38, with IC 50 > 200 μM comparable to sorafenib (IC 50 = 192 μM). In vitro enzymatic assays, 2h and 2l derivatives emerged as potent multi‐kinase inhibitors targeting VEGFR‐2, EGFR, and HER‐2 with IC 50 = 0.20, 0.21, and 0.19 μM, respectively, and IC 50 = 0.67, 0.53, and 0.40 μM, respectively, hence circumventing cancer resistance mechanisms. The most potent Compound 2h prompted apoptosis and necrosis at % G0‐G1 phase in HCT‐116 via the activation of caspase‐3 and 8, with significant downregulation of anti‐apoptotic protein Bcl‐2. Additionally, Compound 2h markedly suppressed immunomodulatory proteins TNF‐α and IL‐6 levels by 80.9% and 88.2%, respectively, in comparison to dexamethasone (82.7% and 93.2%, respectively), which attenuates tumor‐promoting inflammation, disrupting pro‐survival signaling pathways and metastasis. In silico ADMET, toxicity, and molecular docking studies were performed; notably, the docking simulations generated an interesting hypothesis for potential direct binding to Bcl‐2, an effect distinct from the experimentally observed downstream downregulation of its expression. The present results pave the way for further developing of 2h candidate as a multi‐tyrosine kinases inhibitor toward colon cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsVascular Endothelial Growth Factor Receptor-2PyrimidinesErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsHumansErbB ReceptorsMolecular Docking SimulationCell ProliferationMCF-7 CellsCell Line, TumorHCT116 CellsStructure-Activity RelationshipApoptosisTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

EGFRHER‐2PyrimidineVEGFR‐2immunomodulatoryin silico analysismulti‐kinase inhibitors

Substanzen

ErbB ReceptorsAntineoplastic AgentsVascular Endothelial Growth Factor Receptor-2PyrimidinesEGFR protein, humanErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsERBB2 protein, humanKDR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Ain-Helwan, Cairo, Egypt.
  • Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Capital University (Formerly Helwan University), Ain-Helwan, Cairo, Egypt.
  • Department of Inorganic and Organic Chemistry, ESTCE, Universitat Jaume I, Castellón, Spain.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, El Saleheya El Gadida University, El Saleheya El Gadida, Egypt.

Zitieren

APA

Ahmed, N. M., Gaballah, M. S., Altava, B., & Lotfallah, A. H. (2026). Pyrimidine‐Derived Scaffolds Targeting VEGFR‐2, EGFR, and HER‐2: Synthesis, Anticancer/Immunomodulatory Evaluation, and In Silico Analysis. Drug Development Research, 87(3). https://doi.org/10.1002/ddr.70314

Vancouver

Ahmed NM, Gaballah MS, Altava B, Lotfallah AH. Pyrimidine‐Derived Scaffolds Targeting VEGFR‐2, EGFR, and HER‐2: Synthesis, Anticancer/Immunomodulatory Evaluation, and In Silico Analysis. Drug Development Research. 2026;87(3). doi:10.1002/ddr.70314

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Naglaa M and Gaballah, Mohamed S and Altava, Belen and Lotfallah, Ahmed H},
  title = {Pyrimidine‐Derived Scaffolds Targeting VEGFR‐2, EGFR, and HER‐2: Synthesis, Anticancer/Immunomodulatory Evaluation, and In Silico Analysis},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {3},
  doi = {10.1002/ddr.70314}
}
Kostenlos starten →